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The Swiss Childhood Cancer Registry (SCCR) is the national 
population - based cancer registry for children and adolescents 
in Switzerland. New cancer diagnoses, clinical information, de-
tails on treatment and long-term follow-up (survival, second 
primary neoplasms and late effects) have been registered in 
the SCCR since 1976. With many associated research projects 
and through close collaboration with clinicians it contributes 
to understanding the causes of cancer in children, improving 
follow-up care and reducing late effects.
The SCCR is located at the Institute of Social and Preven-
tive Medicine (ISPM) at the University of Bern. It is operated 
jointly by the Swiss Paediatric Oncology Group (SPOG) and the 
University of Bern. Since 1976, all nine Swiss paediatric haema-
tology - oncology centres report newly diagnosed cases to the 
registry and send annual updates on clinical follow - up. Since 
2007, the SCCR also collects supplementary data from other 
sources, including cantonal cancer registries, other hospitals, 
pathology laboratories and the Swiss Federal Statistical Office 
(SFSO). As of 31st December 2016, data from of 10391 cases 
(diagnosed in 10250 patients) have been registered. 
The SCCR is authorized to collect non - anonymised data. 
The permission has been issued in 2007 by the Federal Com-
mission of Experts for Professional Secrecy in Medical Research 
(Eidgenössische Expertenkommission für das Berufsgeheimnis 
in der medizinischen Forschung). Since 2014 the new act on 
human research is in place. The SCCR got a new authorization 
issued by the ethics committee of the canton of Bern in July 
2014.
The SCCR is an associated member of the National In-
stitute for Cancer Epidemiology and Registration (NICER), of 
the European Network of Cancer Registries (ENCR) and of the 
International Association of Cancer Registries (IACR), and col-
laborates with childhood cancer registries throughout Europe.
What did the Swiss Childhood Cancer Registry achieve 
in more than 40 years?
 • Performed national childhood cancer monitoring of high 
quality
 • Provided reliable statistical routine data
 • Established a competitive research platform
 • Gave competent ad hoc answers to health- , environmental- , 
  socio- , political- related questions
 • Cooperated closely with all paediatric oncologists, 
 • Established a strong network with Swiss parents organi-
sations
This eighth report covers the routine analyses of all chil-
dren diagnosed between 1st January 1976 and 31st December 
2016. Activities, research and publications of the SCCR are de-
scribed for the years 2016 to 2017. The report contains:
• An overview of the organisation and team of the SCCR, 
SPOG and the participating paediatric haematology - 
  oncology centres (Chapter 2)
• A summary of the data collected in the registry up to 31st 
December 2016 (Chapter 3)
• A summary of current research of the SCCR  (Chapter 4)
• A list of publications (Chapter 5)
Our website (www.childhoodcancerregistry.ch) contains 
further information, including past annual reports and scien-
tific publications.
We would like to thank all the children and their families, 
and all adolescent and adult childhood cancer survivors, for 
allowing us to collect their data. We also thank the physicians 
and clinical research coordinators of the Swiss Paediatric On-
cology Group for their excellent collaboration. Our thanks also 
go to the cantonal cancer registries, the National Institute for 
Cancer Epidemiology and Registration (NICER), the Swiss Fed-
eral Statistical Office (SFSO), the Federal Office of Public Health 
(FOPH) and the pathology laboratories for their cooperation. 
Finally, we thank our supporters for their generous contribu-
tions.
1. Introduction
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2. Organisation of the Swiss Childhood Cancer Registry
The Swiss Childhood Cancer Registry (SCCR) is a member of the Swiss Paediatric Oncology Group (SPOG) and is or-
ganised as a joint operation of the Institute of Social and Preventive Medicine (ISPM) at the University of Bern and the 
SPOG.
2.1 Institute of Social and Preventive Medicine (ISPM), University of Bern
Direction
Claudia Kuehni, Prof MD Head of SCCR claudia.kuehni@ispm.unibe.ch
Gisela Michel, Prof PhD Vice head of SCCR gisela.michel@unilu.ch
 
Swiss Childhood Cancer Registry
Verena Pfeiffer, PhD Project coordinator SCCR verena.pfeiffer@ispm.unibe.ch
Katharina Flandera Administration katharina.flandera@ispm.unibe.ch
Shelagh Redmond, PhD Diagnostic coding, data quality
Parvinder Singh Statistics 
Meltem Altun Data management 
Erika Brantschen Data management 
 
Trust Centre 
Christina Krenger Data management 
 
Informatics and database support 
Rui Ribeiro Database support 
 
Research projects 
Ben Spycher, PhD Senior research fellow, Project manager
Grit Sommer, PhD Senior research fellow, Project manager
Rahel Kuonen, MSc Senior research fellow, Project manager
Christian Kreis, PhD Senior research fellow
Fabien Belle, MSc PhD student
Konstantinoudis Garyfallos, MSc PhD student
Rahel Kasteler, Dr med PhD student
Christina Schindera, Dr med PhD student
Nicolas Waespe, Dr med PhD student
Annette Weiss, MSc PhD student
Swiss Childhood Cancer Registry
Institute of 
Social and Preventive Medicine
Finkenhubelweg 11
CH - 3012 Bern
Switzerland
Tel. +41 (0)31 631 56 70
www.childhoodcancerregistry.ch
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2.2 Swiss Paediatric Oncology Group (SPOG)
SPOG Executive Board 
Felix Niggli, Prof MD President 
Heinz Hengartner, MD Vice president 
Maja Beck Popovic, Prof MD Committee Member 
SPOG Office in Bern 
Isabelle Lamontagne - Müller, MSc Managing director isabelle.lamontagne@spog.ch
Marlise Rohrer Director’s assistant 
Barbara Böttcher, PhD Head Quality assurance  
Julia Ruckstuhl, MSc Head Regulatory affairs 
Tu- My Diep Lai, PhD Regulatory affairs 
Derya Keller, MSc Regulatory affairs  
Silvia Wirth, PhD Regulatory affairs 
Michael Zeller, PhD Regulatory affairs 
Patrizia Specker Partner Relations 
 
Participating centres (paediatric haematology - oncology)
  Head of Division Clinical Research Coordinator
Aarau 
Kinderklinik, Kantonsspital Aarau R. Angst, MD C. Anderegg 
   R. Kusche
   S. Drerup
Basel 
Universitäts - Kinderspital  N. von der Weid, Prof MD V. Stahel
beider Basel [UKBB]  M. Imbach
Bern 
Universitätsklinik für  K. Leibundgut, Prof MD F. Julmy 
Kinderheilkunde, Inselspital  N. Beusch
   N. Amport
Genève 
Hôpital des Enfants, Hôpitaux  M. Ansari, Prof MD R. Lo Piccolo
Universitaires de Genève [HUG]  V. Mattiello, MD
Lausanne 
Service de Pédiatrie, Centre Hospitalier  M. Beck Popovic, Prof MD R. - E. Garcia, MD
Universitaire Vaudois [CHUV]  E. Lemmel
Bellinzona 
Reparto di Pediatria, Ospedale  P. Brazzola, MD P. Brazzola, MD
S. Giovanni, Bellinzona  P. Balestra
Luzern 
Kinderspital, Kantonsspital Luzern J. Rischewski, PD MD J. Garibay
St.Gallen 
Ostschweizer Kinderspital J. Greiner - Lang, MD F. Hochreutener
    A. Schiltknecht
Zürich  
Universitäts - Kinderspital, Zürich F. Niggli, Prof MD H. Markiewicz
  M. Grotzer, Prof MD A. Reinberg
   R. Siegenthaler
   C. Althaus, MD
SPOG Office 
Effingerstrasse 33, 3008 Bern
Tel.: +41 (0)31 389 91 89
www.spog.ch
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2.3 General information
Aims 
The Swiss Childhood Cancer Registry collects information 
on the diagnosis, treatment and follow- up of children and ad-
olescents with cancer in Switzerland, and provides data for na-
tional and international statistics and research projects. 
It aims: 
• To collect representative, population- based data on 
cancer in children and adolescents in Switzerland (cancer 
incidence, prevalence, time trends, regional distribution 
and survival rates)
• To document diagnostic evaluations, treatment and 
participation in clinical trials
• To describe short- term and long- term prognosis (mortali-
ty, morbidity and quality of life) after cancer in childhood 
and adolescence
• To provide a research platform for clinical, epidemiologi-
cal and basic research
It thus contributes to:
• Research into the aetiology of cancer in children and 
adolescents
• Planning of health services 
• Continuous improvement of treatment
• Identifying possible late effects of therapy, with the aim 
to diagnose and treat them early and prevent them in 
the future 
Inclusion criteria
The SCCR registers all children and adolescents aged 0 to 
20 years, resident or treated in Switzerland, diagnosed with:
• Acute and chronic leukaemias, including myelodysplastic 
syndrome
• Lymphomas
• Malignant solid tumours
• Central nervous system tumours (CNS), malignant and 
benign tumours 
• Langerhans cell histiocytosis (LCH), 
  Hemophagocytic lymphohistiocytosis (HLH) 
Since 2014 it also registers children and adolescents diagnosed 
with:
• Aggressive fibromatosis (ICD - O - 3M code 8821 /1)
• Benign /mature teratoma (ICD - O - 3M code 9080 /0)
• Mesoblastic nephroma (ICD - O - 3M code 8960 /1)
• Severe aplastic anaemia (ICD - 10 D61.9)
• Neoplasms of the liver, histologically proven, but no 
malformations
Children and adolescents who are not Swiss residents but 
are diagnosed or treated in Switzerland are registered, but they 
are excluded from analyses of incidence and survival.
Sources of data
 Data on children and adolescents with cancer are collect-
ed from several sources, including: 
• The nine Swiss centres for paediatric oncology and hae-
matology (Chapter 2.2)
• Other hospitals
• Cantonal cancer registries, represented by the National 
Institute for Cancer Epidemiology and Registration 
  (NICER)
• Clinical and epidemiological registries (e.g. brain tumour 
registry, bone tumour registry, Swiss growth registry etc.)
• The Swiss Federal Statistical Office (SFSO; Swiss mortality 
statistics)
• Pathology laboratories 
Most children are reported by one of the nine Swiss cen-
tres for paediatric oncology and haematology. Local clinical 
research coordinators complete forms for all newly diagnosed 
patients. Basic information on diagnosis is later completed with 
information on treatments, remissions, relapses, transplanta-
tions and health outcomes. These forms are sent to the SCCR 
and information is entered into the database. Important medi-
cal documents (e.g. pathology reports) are scanned and stored 
electronically using a pseudonym. Paper copies are destroyed. 
Information on Swiss residency is validated through municipal 
population registers.
For the first five to ten years after diagnosis follow- up data 
is extracted annually from patients’ hospital records by the lo-
cal clinical research coordinators in all paediatric oncology and 
haematology centres (Chapter 3.3). To assess outcomes after 
the children have left the clinic, patients are contacted directly 
with a questionnaire and data is linked to mortality records 
(SFSO) and to records from cantonal cancer registries (Chapter 
4.2). Life status update is assessed through community reg-
istries. For children not treated in a paediatric oncology and 
haematology centre, clinical follow- up from hospitals is often 
not available, but long- term epidemiological follow- up is done 
via questionnaires and by assessment of second primary neo-
plasms and mortality as for the other patients and life status 
update via community registries (Chapter 3.3).
Clinical database
 The current SCCR database was set up in 2007. The fol-
lowing information is routinely collected:
• Tumour diagnosis, date of diagnosis, morphology, to-
pography, stage, metastases
• Other diagnoses (cancer- relevant pre- existing conditions)
• Relevant laboratory and clinical data
• Treatment (clinical trial participation, chemotherapy, radio- 
  therapy, surgical intervention, bone marrow transplanta-
tion) and treatment centres involved
• Follow- up data (changes of treatment, remissions, re-
lapses, survival /death and cause of death)
• Late adverse outcomes (e.g. cardiovascular diseases, 
second primary neoplasms and endocrine disorders) 
12
Trust centre
Since 2010, personal information (name and address) is 
stored in a separate database in the trust centre. The trust cen-
tre validates addresses, residence status, nationality, and vital 
status via community registers. This personal information is 
separated strictly from clinical information of the SCCR data-
base. The following data is collected: 
• Patient name, address of residence at time of diagnosis, 
  current address of residence
• Date of birth, sex, first language
• Country of residence and nationality at time of diagnosis
• Vital status and date of death
• Parental profession, parental date of birth
Tumour coding
 All tumours are coded according to the following interna-
tional classification systems (see appendix): 
• International Classification of Childhood Cancer, third 
edition (ICCC - 3) 
• International Classification of Diseases for Oncology, 
third edition (ICD - O - 3) 
• International Classification of Diseases and Related 
Health Problems, tenth revision (ICD - 10) 
In the annual report, the main diagnostic groups of the ICCC - 3 
are used: 
I.  Leukaemias, myeloproliferative diseases, and myelodys- 
 plastic diseases
II.  Lymphomas and reticuloendothelial neoplasms
III.  CNS and miscellaneous intracranial and intraspinal 
 neoplasms
IV.  Neuroblastoma and other peripheral nervous cell tumours
V.  Retinoblastoma
VI. Renal tumours
VII. Hepatic tumours
VIII. Malignant bone tumours
IX.  Soft tissue and other extraosseous sarcomas
X. Germ cell tumours, trophoblastic tumours, and 
 neoplasms of gonads
XI.  Other malignant epithelial neoplasms and malignant   
 melanomas
XII. Other specified and unspecified malignant neoplasms 
Langerhans cell histiocytosis (LCH), which is not included in 
ICCC - 3, is reported separately.
Data protection
In 2004, the SCCR received a special authorisation (Son-
derbewilligung) from the Swiss Federal Commission of Experts 
for Professional Secrecy in Medical Research. Starting from 
June 2007, a general authorization (Registerbewilligung) ) per-
mitted the data collection from paediatric cancer patients (chil-
dren and adolescents) throughout Switzerland after obtaining 
written, oral or silent consent. 
Since January 2014 the new Human Research Act and its 
three ordinances are in place. Out of those three ordinances, 
the ordinance on Human Research with the exception of Clin-
ical Trials provides the new framework for the SCCR. Instead 
of the Swiss Federal Commission of Experts for Professional 
Secrecy in Medical Research, data collection and storage by 
the SCCR now require an authorisation by the ethics commit-
tee of the canton of Bern. The general authorization (Regis-
terbewilligung) has been replaced in July 2014 by an approval 
from the ethics committee of the canton of Bern. 
Funding
The SCCR thanks the following supporters for their finan-
cial contributions towards the daily operation and the con-
tinuous development of the registry. Supporters of scientific 
research of the SCCR are listed in Chapter 4.
Main funding sources 2015 /2016
• Schweizerische Konferenz der kantonalen Gesundheits- 
  direktoren und - direktorinnen (GDK)
• Schweizerische Pädiatrische Onkologie Gruppe (SPOG) 
• Universität Bern, Institut für Sozial- und Präventivmedizin 
(ISPM)
• Krebsforschung Schweiz 
• Kinderkrebshilfe Schweiz  
Other funding sources 2015 /2016
• National Institute for Cancer Epidemiology and 
  Registration (NICER)
• Federal Office of Health (FOH)
• Kinderkrebs Schweiz
• Celgene GmbH 
  (through Förderverein Schweizer Kinderkrebsregister)
• Amgen Switzerland AG 
  (through Förderverein Schweizer Kinderkrebsregister)
• CSL Behring 
  (through Förderverein Schweizer Kinderkrebsregister)
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3.1 Overview
The SCCR registers all tumours diagnosed and treated in 
Switzerland, classified according to the ICCC - 3 and Langer-
hans cell histiocytosis (LCH) in patients aged 0 to 20 years at 
time of diagnosis. This annual report covers the time period 
from 1st January 1976 until 31st December 2016. The addi-
tional disorders, which are registered since 2014 (see inclusion 
criteria under paragraph 2.3), have not been included in the 
following analyses. Incidence rates are calculated based on the 
number of primary neoplasms (cases). The number of cases 
slightly exceeds the number of patients because patients with 
more than one primary tumour diagnosed before age 20 years 
are counted separately for each new tumour. 
The section on routine analyses includes three chapters:
Chapter 3.2 presents data on all cases registered in the 
SCCR. This includes cases resident in Switzerland or abroad, 
who were diagnosed or treated in Switzerland. 
Chapter 3.3 presents data on cases resident in Switzer-
land, aged 0 to 14 years at diagnosis. This correspondents to 
the age group usually covered in international publications. 
Therefore, tables and figures can be compared with data from 
other countries. Because registration in Switzerland is more 
than 95% complete for this age range with estimated inci-
dence and survival rates close to their true value.
Chapter 3.4 presents data on cases resident in Switzer-
land, aged 15 to 20 years at diagnosis. Patients of this age 
group are treated in a large number and variety of clinics and 
therefore registration is less complete. Ultimately, incidence 
rates cannot be calculated for this age group.
3.2 All cases registered in the SCCR (N = 10391)
This chapter describes data from all cases diagnosed 
1976 - 2016, resident in Switzerland or abroad, diagnosed or 
treated in Switzerland (N = 10391). 
Up to 31st December 2016, a total of 10391 cases classi-
fiable according to the ICCC-3, or Langerhans cell histiocytosis 
(LCH), have been registered in the SCCR. These tumours were 
diagnosed in 10250 patients. Among these, 10250 patients 
had only one primary neoplasm, 137 patients had two primary 
neoplasms and 4 patients had three primary neoplasms at age 
0-20 years. 
The SCCR started in 1976. Initially, only patients aged 0 
to 15 years who participated in clinical trials were registered. 
Non- trial patients have been included since 1982, resulting 
in a significant increase in the number registered. In the early 
1990s, the introduction of the first electronic database further 
increased case registration. Since then, annual registration has 
remained constant (Figure 1).
In the last five years (2012-2016), a total of 1539 newly 
diagnosed cases were registered; among them 1335 cases in 
Swiss residents (Table 1).
Swiss residents account for 9255 (89%) of all cases and 
foreign residents for 1136 (11%) cases (Table 2). Swiss resi-
dents make up 35% (179/513) of all retinoblastoma patients, 
while foreign residents make up 65% (334/513) of these pa-
tients. This is due to the international reputation of the Jules 
Gonin Hospital in Lausanne, which is the national centre for 
retinoblastoma treatment but also attracts many patients from 
abroad.
3. Routine Analyses
300
250
200
150
100
50
0
1976 2000 2004 2008 2012 2016
Year of childhood cancer diagnosis Total   
 Swiss residents
A
nn
ua
l n
um
be
r o
f c
as
es
1980  1984 1988 1992 1996
Figure 1
Annual number of 
registered cases over time
Swiss and foreign residents, age 
at diagnosis 0 - 14 years; period of 
diagnosis 1976 - 2016; all diagnoses 
(ICCC - 3 or Langerhans cell 
histiocytosis); N = 8019
14
 
  Age at diagnosis (years)
 All ages (0 - 20) Children (0 - 14) Adolescents (15 - 20)
Switzerland 9255 89,1 7043 87,8 2212 93,3
Foreign countries 1136 10,9 976 12,2 160 6,7
Europe  803 7,7 710 8,9 93 3,9
Neighbouring countries 431 4,1 369 4,6 62 2,6
          Austria 11 0,1 11 0,1 0 0,0
          France 152 1,5 115 1,4 37 1,6
          Germany 84 0,8 79 1,0 5 0,2
          Italy 183 1,8 163 2,0 20 0,8
          Liechtenstein 1 0,0 1 0,0 0 0,0
Other European countries 372 3,6 341 4,3 31 1,3
Middle East 40 0,4 33 0,4 7 0,3
North Africa 162 1,6 125 1,6 37 1,6
Other African countries 52 0,5 44 0,5 8 0,3
Other countries 65 0,6 56 0,7 9 0,4
Abroad  13 0,1 8 0,1 5 0,2
Total   10391 100,0 8019 100,0 2372 100,0
Swiss and foreign residents, age at diagnosis 0-20 years; period of diagnosis 1976-2016; all diagnoses (ICCC-3 or Langer-
hans cell histiocytosis); N=10391
Table 2 
Total number of cases 
registered in the SCCR, 
by country of residence
Table 1
Total number of 
cases registered in the 
SCCR, by period of 
diagnosis 
   All patients Swiss Foreign  
    residents residents
   Age at Age at Age at 
   diagnosis diagnosis diagnosis  
 Year of diagnosis (years) (years) (years)
   0 - 14 15 - 20 0 - 14 15 - 20 0 - 14 15 - 20
  1976-1981 702 185 622 167 80 18
  1982-1986 789 252 699 233 90 19
  1987-1991 949 292 789 271 160 21
  1992-1996 1050 329 934 296 116 33
  1997-2001 1059 340 949 321 110 19
  2002-2006 1108 393 1022 366 86 27
  2007-2011 1096 308 958 293 138 15
  2012-2016 1266 273 1070 265 196 8
    8019 2372 7043 2212 976 160
Swiss and foreign residents, age at diagnosis 0-20 years; period of diagnosis 1976-2016; all diagnoses (ICCC-3 or Langer-
hans cell histiocytosis); N=10391
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3.3 Swiss residents aged 0 - 14 years 
 at diagnosis (N = 7043)
This chapter reports on cases aged 0 - 14 years and resi-
dent in Switzerland at diagnosis with a tumour coded accord-
ing to ICCC - 3 or a Langerhans cell histiocytosis. Results for 
this age group can be compared directly to data from other 
countries. 
Diagnoses
The International Classification of Childhood Cancer (ICCC - 3) 
distinguishes 12 groups of cancers (Table 3). The most com-
mon are leukaemias (33% of all cancers), followed by tumours 
of the central nervous system (20%; especially brain tumours); 
and lymphomas (12%). Other cancers arise from embryonic 
tissue. These include neuroblastoma (7%) from primitive neu-
ral tissue, nephroblastoma (5%) from renal tissue, hepatoblas-
toma (1%) in the liver, germ cell tumours (3%), and retinoblas-
toma (3%). 
Germ cell tumours may arise in the gonads (ovaries and 
testes), or in other sites, such as the brain (intracranial germ 
cell tumours). Soft tissue sarcomas (7%), and malignant bone 
tumours (4%) arise from abnormal connective tissue. Occa-
sionally, children also develop carcinomas such as melanomas 
or other rare tumours (3%). Langerhans cell histiocytosis (3%) 
is officially not counted as a malignant disease. But as children 
with this disease are treated similarly to those with cancer and 
in rare cases also die, they are recorded in the Swiss Childhood 
Cancer Registry. The relative frequency of the different tumour 
types varies with age (Table 3 and Figure 2). 
 All children By age at diagnosis (years)
  <1 1 - 4 5 - 9 10 - 14
Diagnosis      n % n % n % n % n %
 I Leukaemias, myeoloproliferative diseases 
  and myelodysplastic diseases    2297 32,6 99 14,4 1095 44,7 635 33,7 468 23,2
 II Lymphomas and reticuloendothelial neoplasms  871 12,4 23 3,3 133 5,4 249 13,2 466 23,1
 III Central nervous system neoplasms   1409 20,0 80 11,6 405 16,5 515 27,3 409 20,3
 IV Neuroblastoma and other peripheral 
  nervous cell tumours     472 6,7 197 28,6 215 8,8 40 2,1 20 1,0
 V Retinoblastoma     178 2,5 86 12,5 83 3,4 8 0,4 1 0,0
 VI Renal tumours     358 5,1 51 7,4 207 8,5 88 4,7 12 0,6
 VII Hepatic tumours     67 1,0 22 3,2 25 1,0 9 0,5 11 0,5
 VIII Malignant bone tumours    305 4,3 0 0,0 19 0,8 92 4,9 194 9,6
 IX Soft tissue and other extraosseous sarcomas  471 6,7 51 7,4 135 5,5 120 6,4 165 8,2
 X Germ cell tumours, trophoblastic tumours and 
  neoplasms of gonads     188 2,7 39 5,7 43 1,8 27 1,4 79 3,9
 XI Other malignant epithelial neoplasms and 
  malignant melanomas    203 2,9 5 0,7 10 0,4 44 2,3 144 7,1
 XII Other specified and unspecified malignant neoplasms 14 0,2 2 0,3 4 0,2 1 0,1 7 0,3
  Langerhans cell histiocytosis    210 3,0 34 4,9 74 3,0 59 3,1 43 2,1
   Total      7043 100,0 689 100,0 2448 100,0 1887 100,0 2019 100,0
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2016; all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=7043 
Table 3 - Main diagnostic groups according to ICCC-3, by age at diagnosis 
16
Swiss residents; age at diagnosis 0 - 14 years; period of diagnosis 1976 - 2016; all diagnoses (ICCC - 3 or Langerhans cell histiocytosis); 
N = 7043
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Follow- up information
The SCCR collects follow- up information for patients in several 
ways: 
1. Clinical follow- up is any contact the patient has with 
the paediatric oncology and haematology centre. Annual 
clinical follow- up care in paediatric centres usually ends 
5 - 10 years after diagnosis. Then the patient is officially 
discharged or referred to an adult oncology centre. Alter-
natively clinical follow- up also ends as soon as the patient 
dies. 
2. Long- term epidemiological follow- up for vital status, 
subsequent neoplasms and current health employs four 
complementary approaches:
• Vital status and current address and place of birth are 
updated by contacting municipal population registers. 
Vital status is known for most cases: among the 6980 
patients, 1701 (24%) have died, and 5279 (76%) are still 
alive (Table 4). Among these, most (4813) have been 
followed-up during the past 8 years, 305 (6%) have last 
been followed up between 2004 and 2008, and only 
161 (3%) before 2004. Among the latter, 111 (38 be-
tween 2004-2008 and 73 before 2004) are lost to fol-
low-up, because they moved abroad. 
• Causes of death are retrieved from Swiss mortality sta-
tistics by record linkage.
• Second primary neoplasms are notified via paediatric 
oncology and haematology centres, detected by regular 
comparison with cantonal (regional) cancer registries in 
Switzerland, or self- reported by survivors and then vali-
dated with pathology reports.
• Morbidity and quality of life are assessed by paper 
questionnaires to survivors in the Swiss Childhood Can-
cer Survivor Study and Childhood Cancer Follow- up 
Study (Chapter 4.2).
Table 4 - Follow- up information available in the SCCR
    n %
Alive  5279 75,6
Last clinical follow-up after 2008 4813 91,2
Last clinical follow-up 2004-2008 305 5,8
Last clinical follow-up before 2004 161 3,0
Deceased  1701 24,4
Total  6980 100,0
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2016; all diag-
noses (ICCC-3 or Langerhans cell histiocytosis); N=6980 patients (7043 cases)  
Figure 2 
Main diagnostic groups according to ICCC - 3, by age at diagnosis
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Figure 3 
Survival of patients in the SCCR, 
by period of diagnosis
Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 1976-2016; all diagno-
ses (ICCC-3 or Langerhans cell histiocytosis); 
N=7043; adjusted for age.
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Figure 4 
Survival of patients by diagnostic 
groups according to ICCC - 3
Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 1997-2016 all diagnoses 
(ICCC-3 or Langerhans cell histiocytosis); 
N=3954; adjusted for age.
20
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
5 15
LHC Retinoblastoma
Lymphomas Renal tumours
Other malignant tumours Leukemias
Malignant bone tumours Soft-tissue sarcomas
CNS tumours Neuroblastoma
0 20
Years since diagnosis
Survival
Long- term survival has improved significantly over the last 
decades (Figure 3).
Ten-year survival increased from 53% in children diag-
nosed between 1976 and 1986, to 66% in children diagnosed 
between 1987-1996, 79% in children diagnosed between 
1997 and 2006, and 87% in children diagnosed within the last 
decade (2007-2016). 
Survival varied widely between diagnostic groups. Figure 4
presents survival by diagnostic group according to ICCC - 3 in 
children diagnosed between 1997 and 2016. Of 3954 chil-
dren, 658 (17%) have died. The following numbers describe 
five-year survival for each main diagnostic group: 99% for 
Langerhans cell histiocytosis; 96% for germ cell tumours; 
95% for lymphoma; 94% for retinoblastoma; 93% for renal 
tumours; 86% for children with leukaemia; 79% for neuroblas-
toma; 79% for hepatic tumours; 76% for soft tissue sarcomas; 
74% for central nervous system neoplasms and 73% for ma-
lignant bone tumours.
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Cancer incidence (2007 - 2016) in Switzerland, 
for children aged 0 - 14 years at diagnosis
Table 5 describes the tumours registered in the SCCR 
during the last ten years (2007-2016). Diagnoses are coded 
according to ICCC-3.
The age-standardised incidence (according to the Euro-
pean standard population) of any childhood cancer (not in-
cluding Langerhans cell histiocytosis) was 16,3 per 100‘000 
person-years. Incidence was highest among children aged 2 
years with 23,3 cases per 100‘000 person-years (boys 25,8, 
girls 20,7). Incidence was lowest in 9 year olds with 10,4 cas-
es per 100‘000 person-years (boys 11,5, girls 9,3) (Figure 5 
shows crude incidence rates in Swiss residents; age at diagno-
sis 0-14 years; period of diagnosis 1997-2016; all diagnoses 
(ICCC-3 but not including Langerhans cell histiocytosis); Figure 
6 shows age- and sex-specific incidence rates for age 0-14).
   Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median) Incidence*
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases 665 33,8 1,6 4,8 5,5
 a. Lymphoid leukaemias 538 80,9 1,5 4,7 4,5
 b. Acute myeloid leukaemias 76 11,4 1,7 5,7 0,6
 c. Chronic myeloproliferative diseases 12 1,8 2,0 11,3 0,1
 d. Myelodysplastic syndrome and other myeloproliferative diseases 31 4,7 2,4 7,0 0,3
 e. Unspecified and other specified leukaemias 8 1,2 0,6 4,4 0,1
II Lymphomas and reticuloendothelial neoplasms 216 11,0 1,8 11,3 1,8
 a. Hodgkin lymphomas 99 45,8 0,9 12,6 0,8
 b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 60 27,8 2,5 8,9 0,5
 c. Burkitt lymphoma 54 25,0 9,8 8,2 0,4
 d. Miscellaneous lymphoreticular neoplasms 3 1,4 NA 1,6 0,0
 e. Unspecified lymphomas 0 NA NA NA NA
III CNS and miscellaneous intracranial and intraspinal neoplasms 436 22,1 1,0 6,8 3,6
 a. Ependymomas and choroid plexus tumor 47 10,8 1,1 3,6 0,4
 b. Astrocytomas 190 43,6 1,0 6,8 1,6
 c. Intracranial and intraspinal embryonal tumors 77 17,7 1,0 6,1 0,6
 d. Other gliomas 51 11,7 1,2 6,9 0,4
 e. Other specified intracranial and intraspinal neoplasms 62 14,2 1,1 10,1 0,5
 f. Unspecified intracranial and intraspinal neoplasms 9 2,1 0,8 6,6 0,1
IV Neuroblastoma and other peripheral nervous cell tumours 139 7,1 1,0 1,6 1,2
 a. Neuroblastoma and ganglioneuroblastoma 138 99,3 0,9 1,6 1,1
 b. Other peripheral nervous cell tumours 1 0,7 NA 5,6 0,0
V Retinoblastoma 42 2,1 0,8 0,8 0,3
VI Renal tumours 93 4,7 0,8 3,3 0,8
 a. Nephroblastoma and other nonepithelial renal tumours 88 94,6 0,8 3,2 0,7
 b. Renal carcinomas 5 5,4 0,7 8,5 0,0
 c. Unspecified malignant renal tumours 0 NA NA NA NA
VII Hepatic tumours 20 1,0 2,3 2,4 0,2
 a. Hepatoblastoma 18 90,0 2,6 2,1 0,1
 b. Hepatic carcinomas 2 10,0 1,0 11,5 0,0
 c. Unspecified malignant hepatic tumours 0 NA NA NA NA
Table 5 
Childhood cancer diagnosed in Switzerland 2007 - 2016: number of cases, relative frequency, sex ratio, median age at diagnosis and 
incidence standardised according to the  European standard population, by diagnostic groups according to ICCC - 3
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   Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median) Incidence*
VIII Malignant bone tumours 82 4,2 0,7 11,8 0,7
 a. Osteosarcomas 42 51,2 0,7 11,7 0,3
 b. Chondrosarcomas 2 2,4 1,0 14,0 0,0
 c. Ewing tumor and related sarcomas of bone 37 45,1 0,9 11,0 0,3
 d. Other specified malignant bone tumours 0 NA NA NA NA
 e. Unspecified malignant bone tumours 1 1,2 NA 14,7 0,0
IX Soft tissue and other extraosseous sarcomas 137 7,0 1,1 7,2 1,1
 a. Rhabdomyosarcomas 75 54,7 1,0 4,5 0,6
 b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms 8 5,8 3,0 12,2 0,1
 c. Kaposi sarcoma 0 NA NA NA NA
 d. Other specified soft tissue sarcomas 41 29,9 0,9 10,6 0,3
 e. Unspecified soft tissue sarcomas 13 9,5 2,3 8,0 0,1
X Germ cell tumors, trophoblastic tumors, and neoplasms of gonads 59 3,0 1,0 6,3 0,5
 a. Intracranial and intraspinal germ cell tumours 17 28,8 1,4 11,1 0,1
 b. Malignant extracranial and extragonadal germ cell tumours 21 35,6 0,8 0,1 0,2
 c. Malignant gonadal germ cell tumours 20 33,9 1,0 11,1 0,2
 d. Gonadal carcinomas 0 NA NA NA NA
 e. Other and unspecified malignant gonadal tumours 1 1,7 NA 0,8 0,0
XI Other malignant epithelial neoplasms and malignant melanomas 77 3,9 0,6 12,0 0,6
 a. Adrenocortical carcinomas 4 5,2 0,3 5,1 0,0
 b. Thyroid carcinomas 14 18,2 0,4 13,0 0,1
 c. Nasopharyngeal carcinomas 2 2,6 1,0 13,6 0,0
 d. Malignant melanomas 11 14,3 0,4 12,7 0,1
 e. Skin carcinomas 4 5,2 3,0 6,7 0,0
 f. Other and unspecified carcinoma 42 54,5 0,6 11,7 0,3
XII Other and unspecified malignant neoplasms 3 0,2 2,0 0,0 0,0
 a. Other specified malignant tumours 2 66,7 1,0 1,8 0,0
 b. Other unspecified malignant tumours 1 33,3  NA 0,0 0,0
Total (not including Langerhans cell histiocytosis) 1969 100,0 1,2 6,2 16,3 
 Langerhans cell histiocytosis 59 2,9 1,6 6,9 0,5
Total (including Langerhans cell histiocytosis) 2028 100,0 1,2 6,2 16,8
 
* Incidence: newly diagnosed tumours in a one years time period per 100‘000 persons (person-years); NA: not applicable
Swiss residents; age at diagnosis 0-14 years, period of diagnosis 2007-2016, all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=2028
Table 5 Continued
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Figure 6
Age-  and sex- specific incidence 
rates (per 100,000 person- years) in 
Switzerland for the last 10 years
Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 2007-2016; all diagnoses 
(ICCC-3 but not including Langerhans cell 
histiocytosis); N=1969
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Figure 5
Crude incidence rate 
(per 100,000 person-years) in Switzer-
land, by sex and year of diagnosis 
for the last 20 years (1997-2016)
Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 1997-2016; all diagnoses 
(ICCC-3 but not including Langerhans cell 
histiocytosis); N=3883
20.0
15.0
10.0
5.0
0.0
1997
Year of childhood cancer diagnosis
 
Cr
ud
e 
in
ci
de
nc
e 
ra
te
2002 2007 2012 2016
Total
Boys
Girls
21Swiss Childhood Cancer Registry Annual Report  2015/2016  Routine Analyses
3.4 Swiss residents aged 15 - 20 years 
 at diagnosis (N = 558)
Table 6 describes the tumours registered in the last ten 
years (2007 - 2016) diagnosed in adolescent patients (aged 
15 - 20 years at diagnosis, N = 558). Because data on adoles-
cents are currently not complete within the SCCR, we do not 
present incidence rates. In adolescents the sex ratio is closer to 
1 than in those aged 0 - 14 years at diagnosis. 
    Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median)
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases  68 12,3 1,5 16,7
 a. Lymphoid leukaemias  37 54,4 2,4 16,2
 b. Acute myeloid leukaemias  15 22,1 0,9 17,6
 c. Chronic myeloproliferative diseases  8 11,8 0,6 17,9
 d. Myelodysplastic syndrome and other myeloproliferative diseases  8 11,8 1,7 16,7
 e. Unspecified and other specified leukaemias  0 NA NA NA
II Lymphomas and reticuloendothelial neoplasms  142 25,6 0,9 16,9
 a. Hodgkin lymphomas  94 66,2 0,8 16,8
 b. Non-Hodgkin lymphomas (except Burkitt lymphoma)  40 28,2 1,2 17,0
 c. Burkitt lymphoma  6 4,2 2,0 18,0
 d. Miscellaneous lymphoreticular neoplasms  1 0,7 NA 16,6
 e. Unspecified lymphomas  1 0,7 NA 15,3
III CNS and miscellaneous intracranial and intraspinal neoplasms  79 14,2 1,1 16,8
 a. Ependymomas and choroid plexus tumor  8 10,1 3,0 18,3
 b. Astrocytomas  21 26,6 0,8 17,2
 c. Intracranial and intraspinal embryonal tumors  16 20,3 1,3 16,5
 d. Other gliomas  11 13,9 0,8 16,8
 e. Other specified intracranial and intraspinal neoplasms  20 25,3 1,2 16,6
 f. Unspecified intracranial and intraspinal neoplasms  3 3,8 2,0 16,8
IV Neuroblastoma and other peripheral nervous cell tumors  1 0,2 NA 16,3
 a. Neuroblastoma and ganglioneuroblastoma  1 100,0 NA 16,3
 b. Other peripheral nervous cell tumors  0 NA NA NA
V Retinoblastoma  0 NA NA NA
VI Renal tumors  6 1,1 5,0 16,9
 a. Nephroblastoma and other nonepithelial renal tumors  2 33,3 NA 16,0
 b. Renal carcinomas  4 66,7 3,0 17,5
 c. Unspecified malignant renal tumors  0 NA NA NA
VII Hepatic tumors  2 0,4 NA 19,4
 a. Hepatoblastoma  0 NA NA NA
 b. Hepatic carcinomas  2 100,0 NA 19,4
 c. Unspecified malignant hepatic tumors  0 NA NA NA
VIII Malignant bone tumors  49 8,8 1,5 16,2
 a. Osteosarcomas  32 65,3 1,7 16,2
 b. Chondrosarcomas  2 4,1 1,0 16,4
 c. Ewing tumor and related sarcomas of bone  15 30,6 1,1 15,8
 d. Other specified malignant bone tumors  0 NA NA NA
 e. Unspecified malignant bone tumors  0 NA NA NA
Table 6 
Adolescent cancer diagnosed in Switzerland 2007-2016: number of cases, relative frequency, sex ratio, median age at diagnosis   
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Table 6 Continued
    Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median)
IX Soft tissue and other extraosseous sarcomas  40 7,2 1,1 16,9
 a. Rhabdomyosarcomas  12 30,0 1,0 16,2
 b. Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms  5 12,5 1,5 15,8
 c. Kaposi sarcoma  0 NA NA NA
 d. Other specified soft tissue sarcomas  18 45,0 1,0 18,8
 e. Unspecified soft tissue sarcomas  5 12,5 1,5 17,2
X Germ cell tumors, trophoblastic tumors, and neoplasms of gonads  52 9,4 3,0 17,9
 a. Intracranial and intraspinal germ cell tumors  7 13,5 NA 17,2
 b. Malignant extracranial and extragonadal germ cell tumors  0 NA NA NA
 c. Malignant gonadal germ cell tumors  40 76,9 3,4 18,3
 d. Gonadal carcinomas  4 7,7 0,3 15,8
 e. Other and unspecified malignant gonadal tumor  1 1,9 NA 15,7
XI Other malignant epithelial neoplasms and malignant melanomas  113 20,4 0,5 18,5
 a. Adrenocortical carcinomas  0 NA NA NA
 b. Thyroid carcinomas  31 27,4 0,2 18,4
 c. Nasopharyngeal carcinomas  3 2,7 2,0 19,9
 d. Malignant melanomas  31 27,4 0,8 18,9
 e. Skin carcinomas  10 8,8 1,5 19,0
 f. Other and unspecified carcinoma  38 33,6 0,5 18,0
XII Other and unspecified malignant neoplasms  3 0,5 2,0 17,4
 a. Other specified malignant tumors  3 100,0 2,0 17,4
 b. Other unspecified malignant tumors  0 NA NA NA
Total (not including Langerhans cell histiocytosis)  555 100,0 1,1 17,2
 Langerhans cell histiocytosis  3 0,5 2,0 17,0
Total (including Langerhans cell histiocytosis)  558 100,0 1,1 17,2
Swiss residents; age at diagnosis 15-20 years, period of diagnosis 2007-2016, all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=558
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4. Research on childhood cancer
The research of the childhood cancer registry focusses on 
three main topics: Aetiology of childhood cancer, long- term 
outcomes, and follow - up care after childhood cancer or young 
adult cancer. These topics are described with their background, 
aims, methods, recent findings, ongoing studies, and contacts 
in the remainder of Chapter 4. Additional information is avail-
able from the investigators and our website (www.childhood-
cancerregistry.ch). Further, we thank the supporters for their 
generous contributions towards the research projects.
All ongoing studies, their funding sources and the senior 
investigator are summarized in Table 7.
Table 7
Research grants of the SCCR, summary
 No Project name Senior investigator Funding sources Study period   
Aetiology of childhood cancer
 1 Spatial variation of childhood cancer risk in Switzerland and    Spycher BD Swiss Cancer Research 01.2017-12.2018
  associations with traffic-related air pollution   (KFS-4012-08-2016)  
 2 Spatial and spatio-temporal clustering of childhood cancer: Spycher BD Swiss Cancer Research   01.2014-12.2016
  The role of infections and environmental hazards  (KFS-3515-08-2014) 
 3 The spatial epidemiology of childhood cancer in Switzerland  Spycher BD Swiss Cancer Research 01.2014-12.2016
    (KFS-3515-08-2014) 
 4 The role of population mixing and exposure to infections in  Spycher BD Swiss Cancer Research 01.2013-12.2014
  the aetiology of childhood leukaemia: a national cohort study  (KFS-3049-08-2012) 
 5 Childhood cancer and geographically defined exposures  Spycher BD Federal Office of Public Health 03.2013-11.2013
  in Switzerland: a census-based nationwide cohort study  (12.008357) 
 6 Childhood cancer and vicinity of residence to petrol stations   Kuehni CE Federal Office of Public Health  06.2010-02.2013
  and roads: census-based nationwide cohort study (PETROL)  (10.002946) 
 7 Childhood cancer and nuclear power plants in Switzerland:    Kuehni CE Swiss Cancer League   09.2008-02.2011
  A census-based cohort study  (02224-03-2008);
    Federal Office of Public Health
    (08.001616)
Outcome research (Long - term outcomes, follow - up care, international collaboration)
 1 Swiss Childhood Cancer Survivor Study (SCCSS) Kuehni CE Stiftung zur Krebsbekämpfung 01.2017-12.2017
   Kuehni CE, Angst R Cancer League Aarau 01.2012-12.2012
    Kuehni CE,  Cancer League Zurich  08.2010-07.2011
   Bergstraesser E
    Kuehni CE Cancer League Bern  04.2009-03.2010
    Von der Weid NX,   Swiss Cancer League  07.2008-06.2010
   Kuehni CE (KLS-2215-02-2008) 
    Von der Weid NX,   Swiss Cancer League 01.2006-10.2008
   Kuehni CE (KLS-1605-10-2004)   
   Kuehni CE Kinderkrebshilfe Schweiz since 2006
 2 PanCare childhood and adolescent cancer survivor Kuehni CE Swiss Cancer Research 08.2011-07.2014
  care and follow-up studies (PanCareSurFup)  (KFS-02783-02-2011)  
   Kuehni CE EU (FP7-HEALTH-F2-2010- 02.2011-01.2017
    257505; project no. 257505) 
 3 PanCare Studies in Fertility and Ototoxicity to improve  Kuehni CE Swiss Cancer League 07.2014-06.2017
  Quality of Life after Cancer during Childhood, Adolescence   (KLS-3412-02-2014)
  and Young Adulthood (PanCareLIFE)  Kuehni CE EU (FP7-HEALTH-F2-2013- 11.2013-10.2018
    602030; project no. 602030) 
 4 Risk of cancer and long-term mortality in children treated  Mullis P, Kuehni CE Swiss Cancer League 07.2012-12.2013
  with growth hormone: Swiss participation in the   (KLS-2948-02-2012)
  EU FP7 project (SAGhE) Mullis P EU  04.2011-03.2014
    (FP-HEALTH-F2-2009-223497)  
   Mullis P,  Kuehni CE Swiss Cancer League 07.2010-12.2012
    (KLS-02586-02-2010)
 5 Mortality after cancer in childhood and adolescence  Kuehni CE Swiss National Science  08.2012-08.2015
    Foundation (PDFMP3_141775)  
   Kuehni CE Swiss Bridge
 6 Dietary habits, nutrition and risk of late effects after Bochud M, Kuehni CE Swiss Cancer League  07.2015-06.2018
  childhood cancer  (KLS-3644-02-2015) 
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No Project name (continued) Senior investigator Funding sources Study period   
 7 Pulmonary dysfunction after childhood cancer:   Kuehni CE Swiss Cancer Research 09.2017-08.2020
  diagnosing early stage disease  (KFS-4157-02-2017) 
 8 Lung problems after childhood cancer: Implementation Sommer G Kinderkrebs Schweiz 06.2017-05.2018
  of a structured follow-up care in Switzerland
 9 Pulmonary late-effects in long-term childhood cancer  Sommer G, Goutaki M Cancer League Bern 01.2017-02.2018
  survivors – Development of guidelines for follow-up care  Lung League Bern 
 10 Cardiovascular disease after childhood cancer:  Von der Weid NX,   Swiss Cancer League 01.2017-12.2019
  diagnosing early stage disease Kuehni CE (KLS-3886-02-2016) 
 11 Improving follow-up care of childhood cancer: Michel G,  Krebsforschung Schweiz  04.2017-03.2020
  implementation of screening for psychological distress Scheinemann K (KFS-3955-08-2016) 
 12 Needs for psychosocial care after childhood cancer  Michel G Krebsforschung Schweiz 06.2017-05.2019
  – A mixed methods study  (HSR-4080-11-2016) 
 13 Psychological late effects in long-term childhood cancer Michel G Krebsliga Zentralschweiz 11.2015-10.2017 
  survivors – Development of guidelines for follow-up care
 14 Follow-up care after childhood and young adult Michel G Swiss National Science 08.2009-08.2014
  cancer (CCFU)   Foundation (PZ00P3_121682 
    and PZ00P3_141722)   
 15 Effectiveness of transition from paediatric to adult care Michel G Swiss Cancer League  04.2011-04.2014
  after childhood cancer   (KFS-02631-08-2010) 
 16 Parents of long-term childhood cancer survivors Michel G Swiss National Science Foun- since 2013
    dation (100019_153268/1) 
    Kinderkrebshilfe Schweiz 
 17 Fertility after Chemo- and Radiotherapy in Childhood Michel G Kinderkrebshilfe Schweiz since 2012
  and Adolescence, FeCt – Multicentre 
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4.1 Aetiology of childhood cancer
 Background
The aetiology of childhood cancers remains largely un-
known. For leukaemia, the most frequent childhood cancer, 
known risk factors include trisomy 21, certain rare genetic 
syndromes, some common germline genetic variants, high 
birthweight, and high parental age at birth. Regarding envi-
ronmental exposures, only ionising radiation at medium to 
high doses is an established risk factor – both for leukaemia 
and CNS tumours. Numerous other environmental factors are 
being discussed as potential risk factors. These include: low 
dose ionising radiation (e.g. natural background radiation and 
diagnostic radiation), traffic related air pollution, electromag-
netic fields (e.g. from power lines, radio and TV transmitters, 
or mobile phones) pesticides, and infections.
 Aims
The broad aims of the group are to investigate: 
• Whether cancer risks in children are associated with 
environmental exposures, such as ionising and non-ion-
ising radiation, air pollution and exposure to infectious 
diseases, as well as parents workplace exposures;
• Whether cancer risks in children are associated with 
socio-economic, family or perinatal exposures;
• The spatial and spatio-temporal distribution of childhood 
cancer cases in order to identify potential environmental 
risk factors.
 Methods
Clinical and residential information on diagnosed cases 
are obtained from the SCCR. Data on the population at risk 
are obtained from the Swiss National Cohort (SNC) which 
includes the entire Swiss resident population at census time 
points (1990, 2000, and annually from 2010 onward). Record 
linkage between the two datasets allows investigating cancer 
incidence on a nationwide scale with a cohort design. The 
SCCR collects geocoded address histories from birth to diag-
nosis allowing to distinguish different exposure time windows. 
Geocoded places of residence are also available for the entire 
population from the SNC. This allows calculating geographical-
ly determined exposures such as distance to highways or NO2 
concentration levels (based on spatial pollution models) for the 
entire population at risk. The SNC also provides demographic, 
socioeconomic and perinatal data for the entire population. 
The availability of precise geocodes of residence allows inves-
tigating spatial and spatio-temporal clustering or identifying 
areas of higher risk (disease mapping) using methods for point 
pattern data rather than methods for less precise regional 
count data (e.g. aggregated at municipality level).
 Current status
A, Recent findings: A summary of our recent research and 
findings is given in [Lupatsch-2016a]. We found evidence of in-
creased risks of childhood leukaemia and CNS tumours among 
children exposed to higher levels of natural background radia-
tion (terrestrial gamma and cosmic radiation) [Spycher-2015a, 
2015b, 2015c]. Young children living in the immediate prox-
imity (<100m) of highways were found to have an increased 
leukaemia risk [Spycher-2015d]. We found little evidence of 
associations between childhood leukaemia and commonly 
used measures of population mixing [Lupatsch-2015b, c] or for 
associations between leukaemia risk and socioeconomic status 
[Adam-2015]. However we did find evidence of a temporal 
association between childhood leukaemia and periods of rapid 
population growth in Swiss municipalities [Lupatsch-2016d]. 
We found evidence for spatio-temporal clustering of leukae-
mia around the time of birth but not around the time of diag-
nosis [Kreis-2016] and this clustering was associated with the 
TEL-AML1 (ETV6-RUNX1) cytogenetic subtype [Kreis-2017]. In 
contrast, we found little evidence of purely spatial clustering 
for childhood leukaemia [Konstantinoudis-2017].
B, Ongoing studies: In ongoing studies we are investigat-
ing whether: i) Childhood cancer is associated with increased 
air concentrations of benzene and NO2; ii) Childhood leukae-
mia is associated with perinatal characteristics (including pa-
rental age, birth order, age difference to next older sibling, 
and birth weight); iii) There is spatial clustering of childhood 
cancers other than leukaemia; and iv) There are specific areas 
of increased risk of childhood cancers in Switzerland (disease 
mapping). Furthermore, we are v) collaborating in an interna-
tional case control study on the association between child-
hood cancer and proximity to power lines.
 Contact
The research team consists of Ben Spycher, Claudia Kuehni, 
Christian Kreis and Garyfallos Konstantinoudis.
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4.2 Long- term outcomes
 Background
Childhood cancer is the most common disease-related 
cause of death in childhood in the western world. Thanks to 
therapeutic improvements in the past decades, survival rates for 
childhood cancer now exceed 80%, leading to a growing popu-
lation of long-term survivors. However, cancer and its treatment 
can cause adverse late effects, such as second primary malig-
nancies, heart and lung disease, hearing loss, and infertility. 
These adverse late effects may impact survivors’ health, health 
behaviour and quality of life, and may lead to premature death. 
Comprehensive data on the burden of late effects of childhood 
cancer including premature mortality and their risk factors are 
scarce. The SCCR has a broad research program focusing on 
long-term outcomes including the national Swiss Childhood 
Cancer Survivor Study (SCCSS), prospective, clinical studies on 
lung and cardiovascular diseases, and a study on cause-specific 
long-term mortality. 
 Aims 
The group aims: 
• To investigate prevalence, incidence and spectrum of 
somatic and psychosocial outcomes including second 
primary neoplasms, somatic health, mental health, ed-
ucational and social outcomes, health-related quality of 
life, and cause-specific long-term mortality.
• To determine sociodemographic, cancer- and treatment 
related predictors associated with long-term outcomes.
• To describe health behaviours in long-term survivors.
• To investigate and improve follow-up care after child-
hood cancer among long-term survivors.
 Methods
This cohort is based on children and adolescents regis-
tered in the SCCR. 
Study population: Eligible are all individuals, who have been 
diagnosed with cancer at age <21 years, who survived at least 
five years, were alive at the time of the study, and who were Swiss 
residents at time of diagnosis. 
Collected data: A detailed questionnaire is sent to child-
hood cancer survivors and their parents to obtain data about 
somatic, psychosocial, and mental health outcomes. For com-
parison, a similar questionnaire is sent to siblings of survivors. 
Questionnaire data are complemented with phone interviews 
to patients and are validated with information from general 
practitioners and hospital records, e.g. audiometric or lung 
function tests to validate hearing problems or lung diseases. A 
second questionnaire is sent to participating survivors to find 
out whether their health has changed over time. We invite 
subgroups of survivors for clinical investigations to paediatric 
oncology centres to investigate their lung and heart functions 
and we collect saliva and urine samples for genetic and met-
abolic analyses. Additionally, we collect data from municipal 
population registries to obtain vital status and date of death, 
and Swiss mortality statistics to obtain causes of death. This 
broad approach makes it possible to investigate prevalence 
and incidence of adverse late effects in Swiss survivors and to 
identify predictors for their occurrence.
Response rate: For the SCCSS questionnaire survey, we 
contacted 4140 five-years survivors aged 0-<20 years at diag-
nosis, 2876 (70%) completed our questionnaire. Among the 
participating survivors, we contacted 1586 survivors with a 
second questionnaire, and currently 804 (51%) survivors com-
pleted the second questionnaire. This survey is still ongoing. 
We also contacted 1522 siblings of childhood cancer sur-
vivors, of which 866 (57%) participated.
 Current status
A, Recent findings
These ongoing studies provide the first national data on 
adverse late effects, health behaviour, survival and long-term 
mortality, and causes for mortality after childhood and adoles-
cence cancer in Switzerland. We analyse and publish our find-
ings continuously. Previous publications reported on health-re-
lated quality of life, education, cognitive problems, partnership, 
income, physical activity, lung disease, cardiovascular disease, 
hearing loss, nutrition, overweight, survival, and mortality. Our 
findings will help to identify patients who are at great risk for 
late effects, to adjust therapies, and to develop tailored fol-
low-up programs for survivors.
Health- related quality of life (HRQoL): We also showed 
that survivors achieved similar educational levels than the 
general population [Kuehni-2012]. Survivors younger than 
20 years were more likely to report cognitive problems than 
their siblings [Wengenroth-2015]. We found lower personal 
income in survivors than in siblings [Wengenroth-2016]. How-
ever, survivors’ personal income may increase in a later stage, 
as treatment pushes back educational training and may cause 
them to start working later than their peers. Survivors are less 
likely to be married or in a life partnership than peers [Wen-
genroth-2014], this might be because survivors take longer to 
reach their final education achievement and this might encour-
age survivors to delay marriage.
Educational and social outcomes: We also showed that 
survivors achieved educational levels similar to the general 
population [Kuehni - 2012]. Survivors younger than 20 years 
were more likely than their siblings to report cognitive prob-
lems [Wengenroth - 2015]. We found lower personal income 
in survivors than in siblings [Wengenroth - 2016]. However, sur-
vivors’ personal income may increase later because treatment 
can push back education and carreer training and cause sur-
vivors to start working later than their peers. Survivors are less 
likely than peers to be married or in a life partnership [Wen-
genroth - 2014]. This might be because survivors take longer to 
reach their final educational achievement, which might in turn 
encourage them to delay marriage.
Physical activity: We found that daily physical activity 
and sport levels in survivors were similar to the general pop-
ulation. Physical activity was mainly determined by socio-de-
mographic and cultural factors [Rueegg-2012a]. However, 
we found that survivors are at high risk of suffering from 
performance limitations in sports and daily living activities 
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but these limitations differed strongly between diagnostic 
groups [Rueegg-2012b]. Despite these physical performance 
limitations, many survivors maintained healthy activity levels 
[Rueegg-2013].
Nutrition: We showed that the adherence to dietary rec-
ommendations among survivors was similar to their siblings 
and the general population, but overall poor [Belle-2016]. 
Hearing loss: We found that the burden of hearing loss as 
a late effect after ototoxic cancer treatment has stabilized in re-
cently treated survivors, suggesting that survivors have benefited 
from new treatment regimens that use less ototoxic radiation 
and carefully dosed platinum compounds [Weiss-2017]. We also 
found that questionnaires are useful to assess hearing in large 
cohorts of childhood cancer survivors, but they underestimate 
mild and unilateral hearing loss. [Weiss-2017].
Lung diseases: We found that five-year survival of children 
diagnosed with cancer in Switzerland improved from 64% in 
1976-1983 to 88% in 2004-2013, but there is room for fur-
ther improvement. Survival rates varied by type of clinical treat-
ment, language region and nationality. All paediatric cancer 
patients should be referred to a specialised paediatric cancer 
centre [Schindler-2017].
Mortality: We found that five-year survivors of childhood 
cancers suffer from an elevated mortality compared to the 
general population, with recurrence and progression of the 
original cancer as the most common causes of death up to 24 
years after diagnosis [Schindler-2016]. 
 B, Ongoing studies 
Ongoing studies focus on different somatic health prob-
lems and health behaviours:
i) lung diseases; ii) cardiovascular diseases; iii) hearing 
loss; and v) dietary habits and overweight. In addition, we 
investigate how follow-up care is performed in patients at risk 
for lung diseases and we actively participate in the develop-
ment and implementation of clinical guidelines for follow-up 
care in Switzerland. We are currently setting up a project for 
the collection of germline DNA of all childhood cancer pa-
tients for pharmacogenetic studies. Furthermore, we collabo-
rate in international studies (see International collaborations).
 Contact
The research team consists of Claudia Kuehni, Fabiën Belle, 
Rahel Kasteler, Rahel Kuonen, Christina Schindera, Grit Som-
mer, Nicolas Waespe, Annette Weiss, Gisela Michel, and Nico-
las von der Weid.
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4.3 International collaborations 
 Background
Late effects of childhood cancer and its treatment are 
common, but numbers in individual countries are low. There-
fore, pooling of data to large international cohorts is essential 
to identify risk factors for late effects using observational data 
and genetic tools. Survivors can benefit from personalized, ev-
idence-based care based on their individual risk; and future 
patients may benefit from adapted treatment, that cause less 
severe side effects. 
International studies on childhood cancer often also in-
clude systematic reviews that summarize the evidence on risk 
factors of late effects. These provide the basis for creating new 
guidelines for the clinical long-term follow-up of survivors of 
cancer diagnosed at a young age.
The SCCR collaborates with other childhood cancer co-
horts [Bhatia-2015, Winther-2015], participates in European 
studies to investigate late effects, and is involved in the devel-
opment of international guidelines for clinical long-term fol-
low-up of childhood and adolescent cancer survivors.
 Aims
Within the international collaborations, we aim to investigate:
• Prevalence and incidence of late effects of childhood and 
adolescent cancer and its treatment
• Risk factors for these late effects
And to develop guidelines to improve the health and qual-
ity of life of current and future survivors of childhood cancer.
 Methods
Swiss patients of childhood and adolescence cancer are 
part of a Pan-European cohort. Researchers within this Europe-
an collaboration can then select patients with late effects, for 
example patients with a second primary cancer, cardiovascular 
or hearing problems, for nested case-control or case-cohort 
studies. Within these studies, researchers can identify non-ge-
netic and genetic risk factors of late effects.
Experts and the International Guideline Harmonization 
Group (IGHG, http://www.ighg.org/) write up systematic re-
views to develop evidence-based, standardised guidelines for 
clinical follow-up of survivors.
 Current status
A, Ongoing studies:
Currently, we are collaborating in two ongoing studies:
PanCareSurFup (PanCare childhood and adolescent can-
cer survivor care and follow-up studies; http://www.pancare-
surfup.eu/) 
This project investigates the burden and risk factors of 
the most severe and life threatening late effects, namely sec-
ond primary neoplasms, cardiovascular disease and premature 
death. We contributed with 4719 Swiss five-year survivors to 
the Pan-European cohort and with detailed treatment data 
from medical records of 139 Swiss survivors to the European 
nested-case control studies. 
Recent findings: A new method to facilitate valid and con-
sistent grading of cardiac events in childhood cancer survivors 
has been published [Feijen-2014]. Three publications have been 
submitted in 2017 an several other publications are in prepa-
ration. 
PanCareLIFE (PanCare Studies in Fertility and Ototoxicity 
to Improve Quality of Life after Cancer during Childhood, Ad-
olescence and Young Adulthood; http://www.pancarelife.eu/) 
This project investigates hearing loss, infertility and qual-
ity of life. We identified 304 survivors at risk for hearing loss 
and collected their hearing tests. Among the 304 survivors, we 
could contact 221 survivors for the collection of saliva samples 
and153 survivors provided their saliva sample for the analysis 
of genetic risk factors of hearing loss. We contributed ques-
tionnaire data from 1594 survivors on hearing loss, fertility and 
quality of life from the SCCSS. We will be responsible, together 
with the University of Münster in Germany, for the statistical 
analysis of quality of life data from eight European countries.
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B, Development of guidelines
In close collaboration with experts worldwide and the 
International Guideline Harmonization Group (IGHG, http://
www.ighg.org/), we write systematic reviews and develop ev-
idence-based, standardized guidelines for clinical follow-up 
of survivors. We are currently involved as chairs, work group 
(WG) leaders and group members in the development of the 
following guidelines: 
l Hearing loss (ototoxicity)
 • Chairs: Wendy Landier (USA), Richard Cohn (AUS)
 • WG leaders: Claudia Kuehni (CH), Thorsten Langer (DE)
l  Pulmonary dysfunction
 • Chairs and WG leaders: Claudia Kuehni (CH), 
   Andrew Dietz (USA)
l Fatigue, mental health and psychosocial problems
 • Chairs: Gisela Michel (CH), Jordan Gilleland Marchak (USA)
 • Fatigue WG leaders: Kathrin Scheinemann (CH), Gisela  
 Michel (CH)
 • Mental Health WG leaders: Janine Vetsch (CH), Jordan  
 Gilleland Marchak (USA)
 • Psychosocial WG leaders: Katie Devine (USA), Martha  
 Grootenhuis (NL)
 • Metabolic syndrome and obesity
l Overweight/obesity 
 • WG leaders: Kevin Oeffinger (USA), Emily Tonorezos (USA)
l Hypothalamic-Pituitary disorders 
 • Chairs: Hanneke van Santen (NL), Wassim Chemaitilly (US) 
Once the guidelines will be available, all centres of the 
Swiss Paediatric Oncology Group will implement these guide-
lines in Switzerland.
Recent findings: A survey among paediatric oncology/
haematology clinics from 44 European countries found that 
many clinics have insufficient or lack programmes for long-
term follow-up into adulthood for survivors of childhood can-
cer [Brown-2015]. This study showed that available guidelines 
are not universally used throughout Europe and we need to 
further develop and disseminate Pan-European long-term fol-
low-up guidelines.
 Contact
The research team consists of Claudia Kuehni, Fabiën Belle, 
Rahel Kasteler, Rahel Kuonen, Grit Sommer, Annette Weiss, 
Gisela Michel and Nicolas von der Weid.
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4.4 Psychosocial outcomes and follow-up care
 Background
Treatment for cancer in children, adolescents and young 
adults has greatly improved and most patients can be cured 
today. However, more than 50% of survivors of childhood 
cancer suffer from late effects. Similarly, parents might suffer 
long after their child has been cured. To detect and treat late 
effects as early as possible, most survivors should continue to 
attend follow-up care long after their cancer has been cured. 
Follow-up care needs to be constantly updated to meet the 
current status of research. International guidelines summaris-
ing the care needed after different cancers and treatment are 
necessary. Additionally, while various models of follow-up care 
have been described, so far none has been implemented in 
Switzerland. A successful model must not only take clinical as-
pect into account but also survivors’ preferences and needs.
 Aims
The group aims to:
• Describe follow-up care models available across Europe, 
and preferences for a follow-up model among Swiss 
childhood, adolescent and young adult cancer survivors, 
parents and physicians (oncologists and general practi-
tioners)
• Evaluate the transition / transfer from paediatric to adult 
care in survivors of childhood cancer
• Describe psychological and socio-demographic out-
comes, as well as needs in parents of long-term child-
hood cancer survivors
 Methods
To describe follow-up care models in Europe, we invited 
198 clinics and follow-up programmes in Europe to complete 
a questionnaire survey describing the follow-up care available 
at their institution. To assess preferences for different models 
of follow-up care, a questionnaire survey assessed opinions 
and perspectives on both currently used and desired opti-
mal follow-up care among survivors, parents, paediatric and 
adult oncologists / haematologists and family practitioners. 
We evaluated the transition from paediatric to adults among 
childhood cancer survivors using medical records. Finally, we 
will contact parents in a questionnaire survey to assess posi-
tive and negative psychological, familial, and social outcomes 
[Mader-2016]. These outcomes will be compared to the Swiss 
general population.
 Current status
A, Recent Findings: 
Follow-up care: Our survey among European paediatric 
oncology/haematology clinics found that many still are lacking 
programmes for long-term follow-up into adulthood [Essig-
2012, Brown-2015]. Additionally, a large proportion of Swiss sur-
vivors do not attend regular follow-up care [Michel-2011, Reb-
holz-2011, Lupatsch-2016e]. Survivors and their parents desire 
precise information on late effects and follow-up care [Giani-
nazzi-2014a, Vetsch 2015]. Most survivors and parents reported 
preferences for care by a specialist (oncologist) [Vetsch-2016, 
Christen-2016]. Parents’ preferred model of care was paediat-
ric oncologist-led follow-up or follow-up provided by a multi-
disciplinary team [Vetsch-2017]. Furthermore, parents rated 
clinical reasons to attend follow-up more important than sup-
portive reasons [Vetsch-2017].
Psychological late effects: We found that survivors are at 
increased risk for psychological distress [Michel-2010, Gianinaz-
zi-2013, Gianinazzi-2014b, Michel-2015, Gianinazzi-2016] or 
other negative psychosocial outcomes [Wengenroth-2014, 
2015a, 2015b, Kuehni-2012a, Rebholz-2012]..
Transition: In Switzerland, there is no specialised transi-
tion programme for survivors of childhood cancer from pae-
diatric to adult care. We investigated if patients are receiving 
e.g. follow-up information after release from the paediatric 
oncology clinic [Gianinazzi-2015]. Patient-adapted information 
on diagnosis, treatment and future follow-up, provided at the 
time of discharge, was rarely found. 
 B, Ongoing studies: 
The study on parents of childhood cancer survivors will 
be the first population-based study among parents of long-
term survivors of childhood cancer and will shed light on their 
psychological well-being, social outcomes and the needs they 
have for their children and themselves.
 Contact
The research team consists of Gisela Michel, Katharina Ros-
er, Luzius Mader, Julia Bänziger, Janine Vetsch, Salome Chris-
ten, as well as of Claudia Kuehni, and Nicolas von der Weid.
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International Classification of Childhood Cancer  - 
ICCC - 3
The third edition of the International Classification of 
Childhood Cancer (ICCC - 3) represents the standard for pre-
sentation of international data on childhood cancer incidence 
and survival. It applies the rules, nomenclature and codes (mor-
phology, topography and behaviour) of the ICD - O - 3. ICCC - 3 
categories are defined in conformity with international classifi-
cations of the pathology and genetics of childhood cancers. In 
the ICCC - 3, three hierarchical levels have been developed: lev-
el one consists of 12 main diagnostic groups and level two of 
47 diagnostic subgroups. These two levels of the ICCC - 3 allow 
standardised comparison of the broad categories of childhood 
tumours. Level three, an optional «extended» classification, 
comprises two to eleven divisions of selected diagnostic sub-
groups. The division of some diagnostic subgroups, e.g. leu-
kaemia and Non - Hodgkin lymphomas, reflects the availability 
of detailed cytogenetic or molecular information that permits 
homogeneous groups of tumours to be distinguished within 
them and thus allows their separate study. The Swiss childhood 
cancer registry (SCCR) uses level one to three. Only malignant 
neoplasms are classified in ICCC - 3, with the exception of 
non - malignant intracranial and intraspinal tumours. Tumours 
known to occur only rarely in young patients are also included 
in ICCC - 3. The ICCC - 3 is used if data are compared with other 
childhood cancer registries.
International Statistical Classification of Diseases for 
Oncology  - ICD - O - 3
The third edition of the International Statistical Classifica-
tion of Diseases for Oncology (ICD - O - 3) has been developed 
by a working group hosted by the International Association of 
Research in Cancer (IARC) and WHO. The morphology code for 
neoplasm has been revised, especially for lymphomas and leu-
kaemia. In contrast to the International Classification of Diseas-
es, 10th revision (ICD - 10), ICD - O - 3 uses only one set of four 
characters for topography (based on the malignant neoplasm 
section of ICD - 10). The topography code remains the same for 
all neoplasms of that site. The behaviour code is incorporated 
as the fifth digit in the morphology field. It identifies whether 
the tumour is malignant, benign, of uncertain or unknown be-
haviour, in situ, presumed to be primary or secondary. For all 
tumours diagnosed since 1st January 2014 the SCCR uses the 
2011 updates to ICD - O - 3 which include new terms, codes 
and behaviour combinations. This allows e.g. B lymphoblas-
tic leukaemias to be further classified according to their exact 
cytogenetic and molecular characteristics, which are relevant 
for disease prognosis. ICD - O - 3 is used to compare data with 
general cancer registries.
International Statistical Classification of Diseases 
and Related Health Problems  - ICD - 10
The International Statistical Classification of Diseases and 
Related Health Problems (ICD) permits the systematic record-
ing, analysis, interpretation and comparison of mortality and 
morbidity data collected in different regions and at different 
time periods. The ICD has become the international standard 
diagnostic classification for all general epidemiological purpos-
es. The ICD - 10 classification comprises three volumes: Volume 
1 contains the main classifications; Volume 2 provides guid-
ance for users of the ICD; and Volume 3 is the alphabetical in-
dex to the classification. Classification is divided into 21 chap-
ters. The first character of the ICD code is a letter. Each letter 
is associated with a particular chapter, e.g. the letter D is used 
in both chapter II «Neoplasms» and chapter III «Diseases of the 
blood and blood - forming organs and certain disorders involv-
ing the immune mechanism». The topography code in Volume 
3 describes the site and the behaviour of the neoplasm: malig-
nant, secondary or metastatic, in situ, benign or of unknown 
behaviour. The morphology codes listed in Volume 1 are the 
same as those used in the special adaptation of the ICD for 
oncology, the ICD - O97.
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